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A B S T R A C T
Background: Many publications have addressed the problem of weight gain and endocrine abnormalities
in patients treated with sodium valproate (VPA). However, the presence of metabolic syndrome (MetS)
among obese patients with epilepsy on VPA has received little attention.
Methods: Thirty-six patients receiving VPA monotherapy were included in this study to evaluate the
presence of MetS. All patients were interviewed and clinically examined. Blood samples were obtained
after an overnight fast, and an oral glucose-tolerance test was performed. Twenty-eight subjects who
were obese but had no epilepsy and were otherwise well were collected as controls (‘‘simple obesity’’
group).
Results: The two study groups were well matched in terms of age, gender and body mass index. Insulin
resistance measured via homeostasis model assessment (HOMA) index was more severe among the VPA-
treated group (4.91  2.91 vs. 2.00  1.72, P = 0.007). The frequency of the MetS was slightly higher in the
patients with epilepsy compared to controls (47.2% vs. 32.1%, respectively), but this difference was not
statistically signiﬁcant (P = 0.223). Multivariate analysis with stepwise logistic regression revealed low
positive correlations between MetS development, HOMA index (P = 0.029; r = 0.361) and valproic acid dose
(P = 0.049; r = 0.323). These correlations were independent of other clinical parameters.
Conclusions: Our preliminary study suggests that obese patients with epilepsy treated with VPA are at
higher risk of MetS than individuals who are ‘‘simply obese’’ but otherwise well. Therefore, the HOMA
index should be monitored in obese patients who receive VPA therapy, rather than monitoring body
weight alone.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Valproate (VPA) is one of the most frequently prescribed
antiepileptic drugs worldwide. It has a broad spectrum of
antiepileptic activity, both in partial and generalized epilepsies.1
Antiepileptic therapy often takes years, and sometimes lasts the
entire lifetime of patients, thus highlighting the importance of drug
safety throughout the therapy course. Previous studies2–4 have
addressed the problem of weight gain and endocrine abnormali-
ties, such as polycystic ovary syndrome, hair loss, hyperandrogen-
ism, and amenorrhea in VPA-treated patients, which can interfere
with treatment compliance and even limit the use of VPA in clinical* Corresponding author at: Department of Neurology, West China Hospital of
Sichuan University, 37th Guoxuexiang Road, Chengdu, Sichuan 610041, China.
Tel.: +86 28 85422549; fax: +86 28 85422549.
E-mail address: zhoudong66@yahoo.de (D. Zhou).
1059-1311/$ – see front matter  2012 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2012.06.001practice. Signiﬁcant weight gain has been one of the most
frequently experienced problems (10–70%) spanning pediatric to
adult usage of VPA both as an anticonvulsant and as a mood
stabilizer.5–8 VPA treatment is associated with high fasting plasma
insulin (FPI) concentrations,2,9,10 particularly in the subset of
weight gain in children and women. Abnormalities in lipid
metabolic changes, such as levels of triglycerides (TG) and high-
density and low-density lipoprotein cholesterol (HDL-C, LDL-C), in
populations that use VPA have also been frequently discussed.
However, ﬁndings have been generally inconsistent.9,11–13
The term ‘‘metabolic syndrome’’ (MetS) refers to a cluster of
metabolic conditions, such as dysglycemia, dyslipidemia, and
hypertension, which are known precursors of cardiovascular and
cerebrovascular diseases. Recent studies have revealed that
MetS represents an enormous economic burden and is consid-
ered a serious public health problem.14–16 International studies
have shown a high prevalence of MetS among patients with
bipolar disorder who experienced signiﬁcant weight gainvier Ltd. All rights reserved.
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syndrome (MetS) among obese patients with epilepsy on VPA
has received little attention. Verrotti et al.19 conducted a
prospective study that focused on VPA-treated children and
adolescents (mean age was 10.1  4.7 years). The study showed
that 40.4% of the patients exhibited considerably body weight,
whereas 43.5% of the obese patients were diagnosed with MetS at
the end of the 24 months of follow-up. Studies on the incidence of
MetS among Chinese obese patients with epilepsy on sodium
valproate are non-existent. Furthermore, no direct study identify-
ing the relative factors of MetS development among VPA-treated
patients has been published thus far.
This study was conducted to evaluate the presence of MetS
among adult obese patients with epilepsy on VPA. In addition, the




The study was carried out in the Outpatient Department of the
Neurology and Inpatient Department of Endocrinology, West
China Hospital, Sichuan University. The study was approved by the
local ethics committee according to the principles of the
Declaration of Helsinki.
2.1.1. Subjects in the patient group
Chinese Han patients with epilepsy who fulﬁlled the following
criteria were recruited: (1) patients should be between 18 and 70
years, regardless of sex. (2) Patients must have an epilepsy
diagnosis, and the seizure types can be classiﬁed according to the
recommendations of the International League Against Epilepsy
(ILAE).20 Diagnoses were based on typical parameters such as
clinical history and seizure semiology, as well as methods such as
electroencephalography (EEG) and brain imaging. (3) Patients
must be undergoing monotherapy with valproic acid for longer
than 6 months, with a standard recommended VPA dose of 15–
30 mg/kg/d, and show good compliance. Compliance was evaluat-
ed by measuring the serum drug concentration at least once before
the study or based on reports from family members. (4) Patients
should have at least average intelligence, with normal physical and
neurological examinations. Patients who were under a ketogenic
diet, which will likely inﬂuence caloric intake, as well as those who
had medical conditions or existing treatment that can affect
hormone or insulin concentrations (thyroid dysfunction, hepatosis,
and glucocorticoid therapy) were excluded. In addition, women
who were pregnant or breastfeeding were excluded.
2.1.2. Subjects in the control group
Hospital electronic medical record archives were screened for
patients aged 18–70 years, with a discharge diagnosis of ‘‘simple
obesity’’ in the Inpatient Department of Endocrinology, West China
Hospital, between January 1, 2010 and July 1, 2011. The deﬁnition
of ‘‘simple obesity’’ was based on the common perspective reached
at the Third National Conference on Obesity Research in China. All
subjects underwent a series of examinations to exclude secondary
obesity, such as Cushingoid obesity.
2.2. Study protocol
2.2.1. Initial screening examinations
The patients with epilepsy who met the inclusion criteria
mentioned above were clinically and physically examined by two
neurologists, and interviewed by the ﬁrst author. Anthropometric
data such as weight, height, and waist circumference weremeasured while the patients were lightly clothed and without
shoes after approximately 10–14 h of overnight fasting. Measure-
ments were conducted using a calibrated weighing scale, wall-
mounted stadiometer, and tape measure. The results were
recorded to the nearest 0.1 kg, 0.1 cm, and 0.1 cm. Waist
circumference was taken with the subject in a standing position,
at the level midway between the lateral rib margin and the iliac
crest. Body mass index (BMI, deﬁned as the weight in kilograms
divided by the square of height in meters) was calculated. Patients
were included for the next program of our study when their BMI
exceeded 25.0 kg/m2, which was classiﬁed as obese according to
the new BMI criteria for Asians by the regional ofﬁce for the WHO
Western Paciﬁc Region.21 Informed consent was obtained from
each participant who was invited to take part in our study.
2.2.2. Collection of anthropometric and clinical data
Age, gender, waist circumference, BMI, seizure type, duration of
illness, age at onset, dose of drug utilized, response to antiepileptic
therapy, and family history were recorded clearly in a designed
form. Arterial blood pressure was measured through the ausculta-
tory method using a sphygmomanometer, with cuff size suitable
for each patient. Two readings were recorded with approximately
5 min of interval after a 5-min rest while seated. Arterial blood
pressure was considered as the mean of the two measurements.
2.2.3. Collection of biochemical parameters
Fasting blood samples were obtained to assess the levels of total
cholesterol (TCho), TG, HDL-C, LDL-C, and valproic acid plasma
concentration. Alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) were also tested to assess liver function.
An oral glucose tolerance test (OGTT) was subsequently performed
by administering 1.75 g of glucose per kilogram of body weight
(maximum of 75.0 g). Blood samples were taken to measure
plasma glucose, insulin, and C peptide levels during fasting, and at
30, 60, and 120 min after glucose load. All samples were
immediately centrifuged, and the plasma and serum were stored
at 70 8C for batch analysis. Plasma glucose concentrations were
measured using the hexokinase method (YSI2300 STAT PLUS, USA).
Serum insulin was ascertained with an immunoradiometric assay
kit (Huaxi, Chengdu, China), whereas C peptide was measured with
a radioimmunoassay kit (Huaxi, Chengdu, China). TCho, HDL-C,
LDL-C, and TG were measured using a Beckman automated
analyzer (Beckman, Fullerton, CA, USA). Valproic acid plasma
concentrations were determined via the chemiluminescence
technique using an Axsysm system (Abbott, USA).
2.2.4. Collection of control group information
Medical records were reviewed and necessary information
were gathered. The data were compiled in standard forms,
including age, gender, BMI, waist circumference, blood pressure,
plasma levels of TCho, HDL-C, LDL-C, TG, ALT, AST, and OGTT
results (including plasma glucose, insulin and C-peptide level at
fasting and at 30, 60, and 120 min after glucose load).
2.3. Deﬁnition of metabolic syndrome and its constituent elements
(1) The homeostasis model assessment (HOMA) index was
calculated as fasting insulin concentration (mU/mL)  fasting
glucose concentration (mmol/L)/22.5, where higher values
indicated greater insulin resistance.22
(2) Metabolic syndrome was deﬁned using the American Heart
Association/National Heart, Lung, and Blood Institute scientiﬁc
statement.15 Participants were diagnosed with MetS based on
this deﬁnition if any three or more of the following attributes
were present: (1) abdominal obesity determined using the
revised Asia-Paciﬁc criteria suggested by the WHO Western
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80 cm (female); and/or BMI > 25 kg/m2 in both sexes; (2)
impaired fasting glucose (IFG): fasting plasma glucose
5.6 mmol/L; (3) triglycerides 1.7 mmol/L; (4) HDL choles-
terol level < 1.03 mmol/L (male) and <1.29 mmol/L (female);
(5) blood pressure  130/85 mmHg.
2.4. Statistical analysis
SPSS 11.5 statistical software was used for statistical analysis.
Quantitative variables were expressed as means  SD, range, and
median. Categorical data were analyzed using percentages. A two-
sample t-test was used to compare the differences in the mean values.
Differences in percentages were compared using Fisher’s exact or Chi-
square tests. Stepwise logistic regression analysis was performed to
identify the possible predictors of MetS development in obese
epileptic patients during VPA therapy. All statistical results were
considered signiﬁcant if P < 0.05 (two-tailed).
3. Results
Forty-ﬁve obese epileptic subjects who fulﬁlled the inclusion
criteria after the initial screening examinations were recruited
from the Outpatient Department of Neurology, West China
Hospital, Sichuan University from January 1, 2010 to July 1,
2011. Six patients refused to have their blood samples drawn for
the laboratory indicator measurements, one patient had hepatic
dysfunction (ALT, AST 3 times of the normal value), and two
patients were negative for valproic acid in the plasma. Finally, 36
patients (80.0%) were enrolled in this study, including 21 (58.3%)
males and 15 (41.7%) females. Twenty-eight simple obesity
subjects were included as controls. All subjects were of Han
descent; thus, no racial variables were considered.
The clinical details of the patient group are listed in Table 1. The
mean age at the onset of epilepsy was 16.5  9.1 years, and all
patients have been taking sodium valproate for at least half a year
(mean  SD, 3.9  3.4 years). The mean plasma valproic acid level
was 79.8  36.6 mmol/L. Seventeen (47.2%) patients were diagnosed
with generalized tonic–clonic seizures, three (8.3%) patients were
diagnosed with complex partial seizures, and sixteen (44.4%) had
both epilepsy types. Most patients who were included in present
study responded well to VPA monotherapy and 88.9% patients
suffered no seizure in the past six months. Four patients (11.1%) failed
seizure control, but none of them suffered epileptic status. Among
these four patients, one had generalized seizure around three times
per month and three suffered generalized or partial seizures once
every few months. All four patients had VPA monotherapy for at least
one year, where the VPA dose maintenance in the recent three
months were 2000 mg/d in two patients, 1000 mg/d in one and
750 mg/d in another one.
The demographic characteristics and metabolic data of the
patients and controls are shown in Table 2. No signiﬁcant
differences were observed between the groups for age, gender,
and BMI. The biochemical results showed no between-group
differences in waist circumference, TCho, LDL-C, HDL-C, and
triglycerides. Insulin resistance measured using the HOMA index,
had higher values among the obese VPA-treated group than amongTable 1












36 16.5  9.1 17/3/16 6.5[0.5–45.0]the simple obesity group (4.91  2.91 vs. 2.00  1.72, P = 0.007). In
terms of MetS components, the epilepsy patients group tended
toward a higher risk for developing high blood pressure (P = 0.031),
whereas the lower proportion unexpectedly met the criterion for low
HDL-C (36.1%, 60.7%, P = 0.05). None of the controls fulﬁlled the
criteria for IFG, whereas four (11.1%) in the epilepsy patient group did.
The frequency of the MetS was slightly higher in patients with
epilepsy compared to controls (47.2% vs. 32.1%, respectively), but this
difference was not statistically signiﬁcant (P = 0.223). The details are
outlined in Table 3.
In addition, Figs. 1 and 2 show the dynamic results of plasma
glucose and insulin levels during the OGTT. Higher levels of glucose
were detected in the patients group during the early period (fasting
and 30 min after glucose load; P < 0.001 and P = 0.004, respective-
ly) whereas no signiﬁcant differences were observed in the latter
period (60 and 120 min after glucose loading; P = 0.846 and
P = 0.767, respectively). Consistent result trends were observed in
plasma insulin levels (early period, P = 0.009, P = 0.03; later period,
P = 0.142, P = 0.68, respectively).
Stepwise logistic regression analysis revealed no signiﬁcant
correlation between MetS development and clinical characteristics,
including age, gender, seizure duration, VPA medication duration,
and BMI. However, low positive correlations were observed between
the development of MetS and both HOMA index (P = 0.029;
r = 0.361) and valproic acid dosage (P = 0.049; r = 0.323).
4. Discussion
In the past decades, a growing body of literature has
investigated the adverse effects of VPA. Most publications have
focused on weight gain, hyperinsulinemia, and endocrine abnor-
malities.2,6,23 The lack of studies on MetS among VPA-treated
epilepsy patients makes the investigation of the actual situation
among this population interesting. Although the design of our
study did not allow us to estimate the prevalence of the problem,
this study lays the foundation for future studies.
The ﬁrst point of our study was to establish whether MetS is
more common in obese patients with epilepsy on VPA than in
simple obese persons. However, because of the limitation in our
cross-sectional study, data on weight before treatment with VPA
were lacking, thus whether treatment with VPA per se increases
the risk for developing MetS could not be ascertained. The two
study groups were well matched for key variables known to
contribute to the development of MetS (age, gender, and BMI). The
frequency was similar to the result reported by Verrotti et al.,19
although various age groups in the population were included.
Recently, the study of Elmslie et al. on bipolar patients18 showed
that 50% of overweight (BMI > 25 kg/m2) patients who had been
taking sodium valproate for 6 months met the criteria for MetS
compared with 32% of the overweight volunteers recruited from
the general population. Although national ﬁgures on the occur-
rence of MetS among the overweight Chinese population in the
corresponding ages were lacking, a rough idea that the risk of
developing MetS among VPA-treated obese patients possibly
increases was achieved.
The second point of the present study was to describe the









 3.9  3.4 896.9  350.9 79.8  36.6
Table 3
Frequency of metabolic syndrome components in patients and controls groups.
Patients (n = 36) Controls (n = 28) P value
Abdominal obesity (%) 36 (100.0) 28 (100.0) –
SBP  130 mmHg or DBP  85 mmHg (%) 20 (55.6) 8 (28.6) 0.031a
TG  1.7 mmol/L (%) 17 (47.2) 10 (35.7) 0.355a
HDL-C < 1.03 mmol/L (male)/<1.29 mmol/L (female) (%) 13 (36.1) 17 (60.7) 0.050a
IFG (%) 4 (11.1) 0 (0.0) 0.125b
MetS 17 (47.2) 9 (32.1) 0.223a
SBP: systolic blood pressure; DBP: diastolic blood pressure; TG: triglycerides; HDL-C: high-density lipoprotein cholesterol; IFG: impaired fasting glucose; MetS: metabolic
syndrome.
a Pearson Chi-square test.
b Fisher’s exact test.
Table 2
The demographic and biochemical index characteristics of the patients and controls.
Patients (n = 36) Controls (n = 28) P value
Age (year) 27.15  10.57 26.62  8.22 0.886
Male (%) 21 (58.3) 15 (53.7) 0.891a
Body mass index 28.00  1.77 28.52  1.79 0.200
Waist circumference (cm) 96.85  4.85 99.90  2.92 0.210
SBP (mmHg) 129.15  10.98 118.62  13.93 0.043
DBP (mmHg) 84.00  12.57 76.46  11.88 0.129
TG (mmol/L) 1.84  0.95 1.70  0.95 0.699
TCho (mmol/L) 4.78  1.36 4.40  0.70 0.382
HDL-C (mmol/L) 1.33  0.30 1.17  0.30 0.141
LDL-C (mmol/L) 2.85  1.01 2.62  0.65 0.531
Fasting glucose (mmol/L) 5.31  0.57 4.50  0.45 <0.001
Fasting insulin (mU/mL) 20.26  9.56 9.80  8.20 0.009
Fasting C-peptide (nmol/L) 0.94  0.35 0.81  0.23 0.49
HOMA index 4.91  2.91 2.00  1.72 0.007
SBP: systolic blood pressure; DBP: diastolic blood pressure; TG: triglycerides; TCho: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density
lipoprotein cholesterol; HOMA index: (fasting insulin  fasting glucose)/22.5.
a Pearson Chi-square test.
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insulin levels were detected in the patient group. Moreover,
insulin resistance was more severe, which was consistent with
results of previous studies.9–11 In terms of MetS components, the
prevalence of elevated blood pressure was higher among the
patient group, whereas the proportion of individuals who met
the MetS diagnostic criteria for abnormal HDL-C was lower. On
the other hand, the OGTT dynamic result curves showed
signiﬁcantly different levels of glucose and insulin during theFig. 1. Plasma glucose concentrations during OGTT in the patients and controls.early period, which plateaued to similar levels in the latter
period. The underlying mechanisms for these characteristics are
still unclear, but in general, these characteristics possibly
indicate that the development of MetS among obese patients
treated with VPA is different from the general obese population.
Furthermore, the insulin resistance in VPA-treated patients is not
merely a consequence of obesity; other factors are likely
involved. This presumption was supported by the observation
that replacement of VPA with lamotrigine in women withFig. 2. Plasma insulin concentrations during OGTT in the patients and controls.
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decreased body weight within 12 months.24 Therefore, further
prospective design research in this area is needed to answer this
question deﬁnitively.
Studies to date have mostly investigated lipid metabolism, but
with inconsistent ﬁndings. Earlier studies have reported lower
HDL-C and higher TG concentrations in populations that use
VPA,9,25 whereas others have found that VPA has no effect on
changes in lipids.13 Some articles have even suggested that VPA is
associated with increased lipid metabolism, which leads to more
favorable lipid proﬁles, thereby possibly contributing to a
protective effect.26 Although our results cannot completely
elucidate the protective effect of VPA against atherogenesis, the
lower proportion of abnormal HDL-C in the patient group
strengthened the latter opinion.
Explaining why hypertension is another important component
of VPA-treated patients is not difﬁcult. Insulin is a stimulator of the
vasodilator nitric oxide (NO) through insulin-mediated phospha-
tidylinositol 3-kinase (PI3K) signaling and endothelial nitric oxide
synthase (eNOS).27 Insulin signaling through the PI3K pathway in
insulin resistance has been proposed to be impaired, leading to
decreased NO. In addition, hyperinsulinemia may also lead to
increased peripheral vascular resistance because of sympathetic
overactivity and vasoconstriction from its anti-natriuretic effects
and increased antitensinogen II.27
The third point of this study was the examination of the
relevant factors for the development of MetS. Most previous
studies have failed to establish a clear association between
ascertained parameters and MetS in VPA-treated patients. A study
that explored weight gain and insulin resistance in children treated
with valproate illustrated that the administered dose of valproic
acid represents an independent predictor for insulin resistance.2
Accordingly, our study demonstrated that the presence of MetS is
associated with high valproic acid doses but is independent of age,
gender, seizure type, and duration of medication. This ﬁnding has
to be considered an important matter, as the necessary dosage
might be adjusted to minimize the possibility of occurrence of
MetS attributed to valproic acid medication. Our study also
demonstrated that the HOMA index is related to MetS develop-
ment rather than BMI. In line with previous studies, insulin
resistance plays an important role in the development of MetS.27,28
Therefore, the HOMA index should be monitored among obese
VPA-treated patients routinely.
Meanwhile, this study has several limitations, including the
study methodology, limited sample size, and lack of information on
patient weight before VPA medication. Consequently, whether
patient obesity of patient is indeed associated with VPA usage
cannot be ascertained. Hence, further conclusions cannot be drawn.
In summary, the present study suggests that the development
of MetS among obese patients with epilepsy on VPA may be more
frequent than individuals who are ‘‘simply obese’’ but otherwise
well. Rather than monitoring body weight alone, the HOMA index
should be monitored in obese patients who receive VPA therapy,
and appropriate prevention strategies should be planned by
clinicians prescribing VPA to avoid the occurrence of MetS.
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